Start Date
September 30, 2008
Primary Completion Date
October 31, 2009
Study Completion Date
May 31, 2010
IT-101 (12mg/m2/dose)
Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.
IT-101 (15mg/m2/dose)
Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.
5% Dextrose (Placebo)
Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
Schwartz Gynecologic Onclology, PLLC, Brightwaters
Riverside Gynecology & Oncology, Newport News
Gabrail Cancer Center, Canton
University of Minnesota Medical Center, Minneapolis
Decatur Memorial Hospital, Clinical Research Department/ Cancer Care Specialists of Illinois, Decatur
The Methodist Hospital, Houston
Chattanooga GYN Oncology, Chattanooga
Lead Sponsor
NewLink Genetics Corporation
INDUSTRY